Crescent Biopharma, Inc. $CBIO

By Microcap Ledger desk · CIK 0001253689

Facts as of Oct 11, 2026, 08:07 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: Waltham, MA
Fiscal year end: December 31
Shares outstanding: 37,143,940 [10-Q 2026-07-30]
as of 2026-07-27

Sources: [10-K 2026-02-26]

What the company doesAI summary of filing

Crescent Biopharma is a clinical-stage biotechnology company focused on developing cancer therapies. The company is developing CR-001, a PD-1 x VEGF bispecific antibody designed as an immuno-oncology backbone therapy, along with a portfolio of antibody drug conjugates (ADCs) including CR-002 and CR-003. CR-001 entered Phase 1/2 clinical trials in early 2026, while CR-002 and CR-003 are expected to enter trials in 2026. The company has not generated any revenue from product sales and has no approved products. [10-K 2026-02-26]

Segments: CR-001 (PD-1 x VEGF bispecific antibody), CR-002 (PD-L1-directed ADC), CR-003 (ITGB6-directed ADC)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	$1.04M	−$48.12M	−$28.40M	$171.59M	[10-Q 2026-07-30]
FY ended Dec 2025	$10.84M	$153.9K	−$71.53M	$213.19M	[10-K 2026-02-26]
FY ended Dec 2024	—	$37.9K	−$31.10M	$34.77M	[DEF 14A 2026-04-21]

Quarterly cash burn: −$14.20M

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-13	64,483,958	[10-Q 2024-11-13]
2025-02-07	64,513,862	[10-K 2025-02-13]
2025-05-12	64,532,091	[10-Q 2025-05-14]
2025-07-25	13,892,562	[10-Q 2025-07-31]
2025-11-03	13,892,516	[10-Q 2025-11-06]
2026-02-23	27,556,767	[10-K 2026-02-26]
2026-04-24	27,571,935	[10-Q/A 2026-06-22]
2026-07-27	37,143,940	[10-Q 2026-07-30]

Shelf registration: S-3 filed 2026-07-01; declared effective 2026-07-10 [S-3 2026-07-01]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2024-12-26. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2024-12-26	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2024-12-26]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-09-18	Brumm Joshua T	sell	7,837	$16.71	[4 2026-09-18]
2026-09-18	Mcneill Jonathan	sell	3,839	$16.71	[4 2026-09-18]
2026-09-16	Lynch Ryan	sell	240	$17.90	[4 2026-09-18]
2026-09-16	Pinkas Jan	sell	658	$17.90	[4 2026-09-18]
2026-09-16	Im Ellie Eunkyung	sell	623	$17.90	[4 2026-09-18]
2026-09-16	Scalzo Richard William	sell	568	$17.90	[4 2026-09-18]
2026-09-16	Bispham Barbara Harlin	sell	620	$17.90	[4 2026-09-18]
2026-09-16	Brumm Joshua T	sell	1,610	$17.90	[4 2026-09-18]
2026-09-16	Mcneill Jonathan	sell	731	$17.90	[4 2026-09-18]
2026-07-16	Fairmount Funds Management Llc	buy	853,450	$14.50	[4 2026-07-20]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-08-14	13G/A	Beneficial ownership report (5%+ holder)
2026-07-30	424B3	Prospectus or prospectus supplement
2026-07-30	10-Q	Quarterly report
2026-07-30	8-K	Results of operations
2026-07-20	13D/A	Beneficial ownership report (5%+ holder)
2026-07-15	8-K	Other events
2026-07-15	424B5	Prospectus or prospectus supplement
2026-07-14	8-K	Results of operations
2026-07-14	424B5	Prospectus or prospectus supplement
2026-07-01	S-3	Registration statement
2026-06-22	424B3	Prospectus or prospectus supplement
2026-06-22	10-Q/A	Amended report

Facts as of Oct 11, 2026, 08:07 AM UTC. Small caps move fast; check the latest filings.